PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: PathXL

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

‘Dolly the Sheep’ Business Mastermind Joins PathXL - PathXL welcomes one of UK’s leading medtech minds onto their Board - PathXL.com
‘Dolly the Sheep’ Business Mastermind Joins PathXL

 

NewswireToday - /newswire/ - Belfast, Northern Ireland, Ireland, 2013/01/22 - PathXL welcomes one of UK’s leading medtech minds onto their Board - PathXL.com. NYSE: PHG, AEX: PHIA

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

One of the leading names in the UK’s healthcare technology sector, Professor Simon Best, has joined the Board of PathXL. The Northern Ireland Science-Park based company, a Queen’s University Belfast spin-out, is a pioneer in the use of web-based solutions for digital pathology.

Chief Executive Des Speed said:
“We are really delighted to welcome someone of Simon’s stature, with over 27 years’ experience in the healthcare, food and agriculture, chemicals and industrial biotechnology sectors, to the PathXL board.

“In this time, he has founded several major bio-pharmaceutical and med-tech businesses and gained significant entrepreneurial and senior management experience in raising finance, deal formation and product commercialisation.

“Simon’s expertise will clearly help PathXL grow as a company and progress the delivery of new patented technology and new products that we plan to take to market in a very assertive way.”

As CEO, it was Prof Best, who was responsible at Roslin Biomed for the commercialisation of the technology used to create Dolly the sheep. Overall, he has helped raise over £170m for lifescience companies in the past 15 years through Angel and Venture fund-raisings, trade-sales and flotations on both AIM and the main-board London Stock Exchange.

Prof Best said:
“I am delighted to be joining the Board of such an exciting young company. PathXL is at the leading-edge of digital pathology which is a ‘hot’ field whose time has definitely come.

“The company is poised to speed up the diagnosis and selection of targeted therapies for patients thereby generating very substantial financial returns to its investors.”

PathXL (pathxl.com), who recently announced a new seven-figure investment into the further development of its innovative digital pathology software, have new projects coming up in 2013 on image analysis.

One of the investors is Crescent Capital and Bob McGowan-Smyth has also just joined the PathXL board to represent the NI-based investment company.

Mr McGowan-Smyth is an experienced venture capitalist and has been a Board member of over 20 commercial organisations. His specialties are: private equity, venture capital, non-executive director, strategic and business planning, mergers and acquisitions, HR issues, management and financial accounting and branding.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PathXL

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


‘Dolly the Sheep’ Business Mastermind Joins PathXL

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

PathXL |
Publisher Contact: Press Office - PathXL.com 
+44(0)28 9073 8712 sales[.]pathxl.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PathXL securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PathXL / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)